Last reviewed · How we verify
NCT06692387: STEPWISE
A Smartphone Based, Titrated Exercise Solution for Patients With Parkinson's Disease in Daily Life: Pilot Study
NA trial testing Step count increase with the use of a motivational application in Movement Disorders in 30 participants. Completed in 1 April 2021.
1 April 2021
Quick facts
| Lead sponsor | Radboud University Medical Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 2 November 2020 |
| Primary completion | 1 April 2021 |
| Estimated completion | 1 April 2021 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Step count increase with the use of a motivational application
Conditions studied
- Movement Disorders — all drugs for Movement Disorders →
- Parkinson Disease — all drugs for Parkinson Disease →
Sponsor
Radboud University Medical Center
Who can join
Eligibility, any sex, with Movement Disorders or Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this pilot randomized controlled trial is to test whether it's feasible to increase participants' step counts within four weeks with a developed motivational smartphone application. If this is feasible, then we can proceed to test the app in a large, long-term randomized clinical trial.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06692387
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Movement Disorders
Currently open trials in the same condition.
- NCT07384442 — Effects of Targeted Temporal Interference Stimulation of Cerebellar Nuclei on Tremor and Gait Disturbance in Parkinson's · NA · recruiting
- NCT05926596 — Leg Stretching Using an Exoskeleton on Demand for People With Spasticity · NA · recruiting
- NCT07236892 — Towards Restoring Complex Movement After Paralysis: Algorithm Development With Healthy Participants · NA · recruiting
- NCT06821230 — Dyadic Mindfulness for People With Parkinson's Disease and Their Caregivers · NA · recruiting
- NCT06088355 — Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease · NA · recruiting
Other Radboud University Medical Center trials
Trials by the same sponsor.
- NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
- NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
- NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
- NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
- NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06692387 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
- Last refreshed: 18 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06692387.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing